Immunotherapy in renal cell carcinoma: A booming clinical research .
| Author | |
|---|---|
| Abstract | :
Nivolumab, an anti-PD1 immune control point inhibitor, is the first treatment that has improved the overall survival of patients after first-line metastatic renal cell carcinoma in 2015. Over the past two years, a large number of trials on these treatments and the interest of associations are being evaluated. |
| Year of Publication | :
2018
|
| Journal | :
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
|
| Date Published | :
2018
|
| ISSN Number | :
1166-7087
|
| URL | :
http://linkinghub.elsevier.com/retrieve/pii/S1166-7087(17)30673-5
|
| DOI | :
10.1016/j.purol.2017.11.005
|
| Short Title | :
Prog Urol
|
| Download citation |